Co-delivery of sorafenib and VEGF-siRNA via pH-sensitive liposomes for the synergistic treatment of hepatocellular carcinoma
Source abstract
Abstract
Non-viral nanocarrier affords a platform for drug and siRNA combination, the focus of which is to load drug and siRNA into a single carrier, allowing for co-delivery and a synergistic effect at tumour site. In our previous study, pH-sensitive carboxymethyl chitosan-modified liposomes (CMCS-SiSf-CL) were assembled for sorafenib (Sf) and Cy3-siRNA co-loaded. The present study evaluated in vitro and in vivo co-delivery of the co-loaded liposomes. Further, in vitro inhibiting hepatocellular carcinoma of the pH-sensitive sorafenib (Sf) and VEGF-siRNA co-loaded liposomes was discussed. The experimental results demonstrated co-delivery and penetration into 2-dimensional (2D) cultured HepG2 cells, 3-dimensional (3D) cultured HepG2 tumour spheroids and tumour regions of H22 tumour-bearing mice. Compared with free siRNA and single loaded carrier, co-delivery liposomes exhibited enhanced VEGF downregulating effect, inducing cell early apoptosis. Therefore, the CMCS-SiSf-CL delivery system can lay the foundation for the co-delivery systems development and provide new area for HCC therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Shandong University
Funding
National Natural Science Foundation of China · Fundamental Research Funds of Shandong University
References (27)
Show source-provided references
1. 10.1016/j.trecan.2015.11.00310.1016/j.trecan.2015.11.003 ↗
2. 10.1002/pon.312310.1002/pon.3123 ↗
3. 10.5858/2000-124-1061-IEOVEG10.5858/2000-124-1061-IEOVEG ↗
4. 10.1158/0008-5472.CAN-06-137710.1158/0008-5472.CAN-06-1377 ↗
5. 10.1016/j.explore.2017.11.00410.1016/j.explore.2017.11.004 ↗
6. 10.1016/S1470-2045(08)70285-710.1016/S1470-2045(08)70285-7 ↗
7. 10.2147/IJN.S9052410.2147/IJN.S90524 ↗
8. 10.1039/C7NR02663C10.1039/C7NR02663C ↗
9. 10.2147/IJN.S13437810.2147/IJN.S134378 ↗
10. 10.1039/C5NR06246B10.1039/C5NR06246B ↗
11. 10.2147/IJN.S14775910.2147/IJN.S147759 ↗
12. 10.1016/j.biotechadv.2014.05.00610.1016/j.biotechadv.2014.05.006 ↗
13. 10.1016/j.biomaterials.2016.01.06110.1016/j.biomaterials.2016.01.061 ↗
14. 10.1016/j.canlet.2015.01.01110.1016/j.canlet.2015.01.011 ↗
15. 10.1002/anie.20131122710.1002/anie.201311227 ↗
16. 10.2217/nnm.13.19210.2217/nnm.13.192 ↗
17. 10.1039/c4nr00018h10.1039/c4nr00018h ↗
18. 10.1038/srep0710710.1038/srep07107 ↗
19. 10.1016/j.jconrel.2018.05.04110.1016/j.jconrel.2018.05.041 ↗
20. 10.1021/mp400640810.1021/mp4006408 ↗
21. 10.1016/j.biomaterials.2014.03.01710.1016/j.biomaterials.2014.03.017 ↗
22. 10.1016/j.addr.2016.05.02110.1016/j.addr.2016.05.021 ↗
23. 10.1016/j.jconrel.2015.07.02010.1016/j.jconrel.2015.07.020 ↗
24. 10.1016/j.jconrel.2014.06.05010.1016/j.jconrel.2014.06.050 ↗
25. 10.1208/s12248-013-9478-210.1208/s12248-013-9478-2 ↗
26. 10.1016/j.intimp.2008.11.02010.1016/j.intimp.2008.11.020 ↗
27. Miao RC, Xu XS, Wang ZX, et al. Synergistic effect of nutlin-3 combined with aspirin in hepatocellular carcinoma HepG2 cells through activation of Bcl-2/Bax signaling pathway. Mol Med Rep. 2018;17:3735–3743.